OTCM
KHRNF
Market cap0USD
May 22, Last price
0.00USD
Name
Khiron Life Sciences Corp
Chart & performance
P/E
0.00
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
228.09%
Revenues
13m
+59.60%
Net income
-33m
L+37.81%
CFO
-20m
L-16.84%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Khiron Life Sciences Corp. is an integrated enterprise focusing on medical and cannabis solutions across Latin America and Europe. Its operations are structured into Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company's primary activities include the cultivation, production, distribution, and international export of medical cannabis, encompassing both tetrahydrocannabinol (THC) and cannabidiol (CBD). Complementing this, Khiron manages a network of health centers and satellite clinics, operating under the ILANS and Zerenia brands, with specific Zerenia clinics established in Medellin and Peru. Furthermore, it develops CBD-infused cosmeceutical products marketed under the Kuida brand. Khiron Life Sciences Corp. was founded in 2012 and maintains its headquarters in Vancouver, Canada.
Key people
Chris Naprawa
President · since 2018
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary, Director · since 2017
Vicente Fox Quesada
Director · since 2018
Director · since 2019
Alvaro Torres
Interim Chairman of the Board, Chief Executive Officer · since 2019
Sruli Weinreb
Director · since 2017
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑05 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||